丹参多酚酸盐、厄贝沙坦同时治疗糖尿病肾病对患者炎性指标水平的影响分析

Effect of Danshen Polyphenolate and Irbesartan on Diabetic Nephropathy in Patients with Inflammatory Index

目的该次实验课题主要探讨糖尿病肾病采用丹参多酚酸盐联合厄贝沙坦进行治疗的临床效果以及对其炎性指标的影响。方法选择2016年7月—2018年7月该院糖尿病肾病患者94例,遵照双盲法分组标准分为研究组、对照组,各47例,分别采用丹参多酚酸盐联合厄贝沙坦治疗与常规治疗,对比两组临床效果与炎性因子水平。结果研究组临床效率为93.62%,与对照组的76.60%相比优势明显(χ~2=5.371 4,P=0.020 4);治疗后对照组白介素-6水平(16.96±2.46)ng/L、C反应蛋白水平(5.82±1.53)mg/L、转化生长因子β1水平(38.26±9.24)ng/L、肿瘤坏死因子α水平(47.43±12.55)ng/L高于研究组(15.90±2.48)ng/L、(4.99±1.33)mg/L、(31.90±9.46)ng/L、(41.82±11.22)ng/L,差异有统计学意义(t=2.080 3、2.806 8、3.297 2、2.284 6,P<0.05)。结论丹参多酚酸盐联合厄贝沙坦应用于糖尿病肾病患者治疗中有可靠效果,能够有效改善炎性因子水平,值得推广。

Objective This experimental study focused on the clinical effects of Danshen polyphenolate combined with irbesartan in the treatment of diabetic nephropathy and its effect on inflammatory markers.Methods A total of 94 patients with diabetic nephropathy from July 2016 to July 2018 were enrolled.The patients were divided into study group and control group according to the double-blind grouping criteria.47 cases in each group were treated with salvianolate and irbesartan treatment and conventional treatment,comparing the clinical effects and inflammatory factor levels between the two groups.Results The clinical efficiency of the study group was 93.62%,which was superior to the control group of 76.60%(χ^2=5.371 4,P=0.020 4).After treatment,the interleukin-6 level(16.96±2.46)ng/L,C-reactive protein level(5.82±1.53)mg/L,transforming growth factorβ1 level(38.26±9.24)ng/L,tumor necrosis factorαlevel(47.43±12.55)ng/L was higher than the study group(15.90±2.48)ng/L,(4.99±1.33)mg/L,(31.90±9.46)ng/L,(41.82±11.22)ng/L,the difference was statistically significant(t=2.080 3,2.806 8,3.297 2,2.284 6,P<0.05).Conclusion Danshen polyphenolate combined with irbesartan has a reliable effect in the treatment of diabetic nephropathy patients,and can effectively improve the level of inflammatory factors,which is worthy of promotion.